Emerging Technologies | Medical
Senolytics are drugs that are being developed to treat age-related diseases by targeting and eliminating senescent cells. These cells are thought to contribute to the decline in function that occurs with age, and senolytics could potentially help to slow down or even reverse this process. There is still much research to be done in this area, but senolytics show promise as a potential treatment for age-related diseases.
Some of the emerging trends in Senolytics include the use of small molecule drugs and biologics to target senescent cells, the development of novel delivery methods to target senescent cells, and the use of senolytics in combination with other therapeutic modalities such as immunotherapy.
See live data on companies, R&D, markets, and news
In order to access the link, you need a Mergeflow account.
Frequently asked questions about the trial
How does the trial work?
After you sign up, you'll receive an email from us with an account activation link. Over the course of the trial, we'll send you emails with tips and tricks. The trial ends automatically after 14 days. No further obligations on your part.
Does the trial include all features?
The trial includes all Analyst Plan features.
Will I be charged when my trial is up?
No. We do not ask for your credit card up front, so you will only be charged when you decide to buy a subscription.
Do I have to install anything?
No. Mergeflow is a SaaS software that runs in any modern web browser. And because it's a subscription, you get constant product updates.
Which payment options does Mergeflow offer?
You can pay your Innovator or Analyst subscription via credit card (American Express, MasterCard, Visa) or SEPA Direct Debits. The larger team plans, API and enterprise solutions can be paid via invoicing and bank transfer.
Does Mergeflow keep my data private?
Yes. We don't serve ads, we never sell anything you give us, and we protect your privacy.